Specialty/Oncology Income Eligibility

For the following products, annual household income must be less than $100,000 regardless of the number of people in the household:

  • FASLODEX® (fulvestrant) Injection
  • IMFINZI® (durvalumab) for Infusion
  • IRESSA® (gefitinib)
  • LYNPARZA® (olaparib) Capsules
  • LYNPARZA® (olaparib) Tablets
  • SYNAGIS® (palivizumab) Injection
  • TAGRISSO® (osimertinib) Tablets